Clinical Trial Update: Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece

View source ↗

Summary

This is a completed real-world 52-week prospective study conducted in Greece to capture reasons for switching to triple therapy with Trixeo Aerosphere in adults…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Trixeo Aerosphere (budesonide/formoterol/glycopyrronium)

Snippet

Sponsor: AstraZeneca | Conditions: Pulmonary Disease, Chronic Obstructive (COPD) | Status: COMPLETED